These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 33393332)

  • 21. Adalimumab versus ustekinumab as first-line biological in moderate-to-severe Crohn's disease: real-life cohort from a tertiary referral center.
    Moens A; Alsoud D; Verstockt B; Sabino J; Ferrante M; Vermeire S
    Eur J Gastroenterol Hepatol; 2022 Oct; 34(10):1015-1020. PubMed ID: 36062494
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study.
    Chaparro M; Baston-Rey I; Fernández-Salgado E; González García J; Ramos L; Diz-Lois Palomares MT; Argüelles-Arias F; Iglesias Flores E; Cabello M; Rubio Iturria S; Núñez Ortiz A; Charro M; Ginard D; Dueñas Sadornil C; Merino Ochoa O; Busquets D; Iyo E; Gutiérrez Casbas A; Ramírez de la Piscina P; Boscá-Watts MM; Arroyo M; García MJ; Hinojosa E; Gordillo J; Martínez Montiel P; Velayos Jiménez B; Quílez Ivorra C; Vázquez Morón JM; María Huguet J; González-Lama Y; Muñagorri Santos AI; Amo VM; Martín-Arranz MD; Bermejo F; Martínez Cadilla J; Rubín de Célix C; Fradejas Salazar P; San Román AL; Jiménez N; García López S; Figuerola A; Jiménez I; Martínez Cerezo FJ; Taxonera C; Varela P; de Francisco R; Monfort D; Molina Arriero G; Hernández Camba A; García-Alonso FJ; Van Domselaar M; Pajares Villarroya R; Núñez A; Rodríguez Moranta F; Marín-Jiménez I; Robles Alonso V; Martín Rodríguez MDM; Camo-Monterde P; García Tercero I; Navarro Llavat M; Arias García L; Hervías Cruz D; Sulleiro S; Novella C; Vispo E; Barreiro-de Acosta M; Gisbert JP
    Inflamm Bowel Dis; 2022 Nov; 28(11):1725-1736. PubMed ID: 35166347
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term Maintenance of Clinical, Endoscopic, and Radiographic Response to Ustekinumab in Moderate-to-Severe Crohn's Disease: Real-world Experience from a Multicenter Cohort Study.
    Ma C; Fedorak RN; Kaplan GG; Dieleman LA; Devlin SM; Stern N; Kroeker KI; Seow CH; Leung Y; Novak KL; Halloran BP; Huang VW; Wong K; Blustein PK; Ghosh S; Panaccione R
    Inflamm Bowel Dis; 2017 May; 23(5):833-839. PubMed ID: 28328624
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and effectiveness of ustekinumab in Crohn's disease: Interim results of post-marketing surveillance in Japan.
    Yokoyama S; Asano T; Nagano K; Tsuchiya H; Takagishi M; Tsujioka S; Miura N; Matsumoto T
    J Gastroenterol Hepatol; 2021 Nov; 36(11):3069-3076. PubMed ID: 34180096
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness and safety of ustekinumab in bio-naïve Crohn's disease patients: a multicentre observational retrospective study.
    Teresa VD; Rául OM; Marisa I; Claudia HG; Esteban FV; Luigi M; Mª Mar MR; Lilyan KC; Luisa CP; Ángel PD; Raquel VL; Noemí MM; Benito VJ; Marta LS; Beatriz LC; Francisco MG; Pau GÁ; Federico AA
    Therap Adv Gastroenterol; 2023; 16():17562848231153560. PubMed ID: 36777363
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacies and Related Issues of Ustekinumab in Japanese Patients with Crohn's Disease: A Preliminary Study.
    Miyazaki T; Watanabe K; Kojima K; Koshiba R; Fujimoto K; Sato T; Kawai M; Kamikozuru K; Yokoyama Y; Hida N; Nakamura S
    Digestion; 2020; 101(1):53-59. PubMed ID: 31722356
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ustekinumab in Crohn's disease: effectiveness and safety in clinical practice.
    Saldaña Dueñas C; Rullán Iriarte M; Elosua González A; Rodríguez Gutiérrez C; Rubio Iturria S; Nantes Castillejo Ó
    Gastroenterol Hepatol; 2020 Nov; 43(9):497-505. PubMed ID: 32703654
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term Clinical Effectiveness of Ustekinumab in Patients with Crohn's Disease Who Failed Biologic Therapies: A National Cohort Study.
    Liefferinckx C; Verstockt B; Gils A; Noman M; Van Kemseke C; Macken E; De Vos M; Van Moerkercke W; Rahier JF; Bossuyt P; Dutré J; Humblet E; Staessen D; Peeters H; Van Hootegem P; Louis E; Franchimont D; Baert F; Vermeire S;
    J Crohns Colitis; 2019 Oct; 13(11):1401-1409. PubMed ID: 30989232
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease: A GETAID multicentre cohort study.
    Fumery M; Defrance A; Roblin X; Altwegg R; Caron B; Hébuterne X; Stefanescu C; Meyer A; Nachury M; Laharie D; Nancey S; Le Berre C; Serrero M; Geyl S; Giletta C; Ah-Soune P; Duveau N; Uzzan M; Abitbol V; Biron A; Tran-Minh ML; Paupard T; Vuitton L; Elgharabawy Y; Peyrin-Biroulet L
    Aliment Pharmacol Ther; 2023 Feb; 57(4):426-434. PubMed ID: 36534763
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ustekinumab for Crohn's disease: a nationwide real-life cohort study from Finland (FINUSTE).
    Eberl A; Hallinen T; Af Björkesten CG; Heikkinen M; Hirsi E; Kellokumpu M; Koskinen I; Moilanen V; Nielsen C; Nuutinen H; Suhonen UM; Utriainen K; Vihriälä I; Soini E; Wennerström C; Nissinen R; Borsi A; Koivunen M; Tillonen J; Sipponen T
    Scand J Gastroenterol; 2019 Jun; 54(6):718-725. PubMed ID: 31184512
    [No Abstract]   [Full Text] [Related]  

  • 31. Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease.
    Battat R; Kopylov U; Bessissow T; Bitton A; Cohen A; Jain A; Martel M; Seidman E; Afif W
    Clin Gastroenterol Hepatol; 2017 Sep; 15(9):1427-1434.e2. PubMed ID: 28365485
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Long-Term Clinical Effectiveness of Ustekinumab in Antitumor Necrosis Factor-Experienced Crohn's Disease Patients.
    Altuwaijri M; Hakami L; Alharbi O; Almadi M; Alshankiti S; Aljebreen A; Azzam N
    Cureus; 2022 Aug; 14(8):e28536. PubMed ID: 36185868
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ustekinumab: "Real-world" outcomes and potential predictors of nonresponse in treatment-refractory Crohn's disease.
    Hoffmann P; Krisam J; Wehling C; Kloeters-Plachky P; Leopold Y; Belling N; Gauss A
    World J Gastroenterol; 2019 Aug; 25(31):4481-4492. PubMed ID: 31496626
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Feasibility of a Clinical Decision Support Tool for Ustekinumab to Predict Clinical Remission and Relapse in Patients With Crohn's Disease: A Multicenter Observational Study.
    Park J; Chun J; Yoon H; Cheon JH
    Inflamm Bowel Dis; 2023 Apr; 29(4):548-554. PubMed ID: 35670522
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationship Between Serum Ustekinumab Trough Concentration and Clinical and Biochemical Disease Activity: A Real-World Study in Adult Patients with Crohn's Disease.
    Nguyen KM; Mattoo VY; Vogrin S; Basnayake C; Connell WR; Ding NS; Flanagan E; Kamm MA; Lust M; Niewiadomski O; Schulberg JD; Wright EK
    Eur J Drug Metab Pharmacokinet; 2023 May; 48(3):271-279. PubMed ID: 36952135
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real World Experience With Ustekinumab in Children and Young Adults at a Tertiary Care Pediatric Inflammatory Bowel Disease Center.
    Dayan JR; Dolinger M; Benkov K; Dunkin D; Jossen J; Lai J; Phan BL; Pittman N; Dubinsky MC
    J Pediatr Gastroenterol Nutr; 2019 Jul; 69(1):61-67. PubMed ID: 31058718
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-world effectiveness and safety of ustekinumab for the treatment of Crohn's disease: the Scottish ustekinumab cohort.
    Plevris N; Fulforth J; Siakavellas S; Robertson A; Hall R; Tyler A; Jenkinson PW; Campbell I; Chuah CS; Kane C; Veryan J; Lam WL; Saunders J; Kelly C; Gaya D; Jafferbhoy H; Macdonald JC; Seenan JP; Mowat C; Naismith G; Potts LF; Sutherland DI; Watts D; Arnott I; Bain G; Jones G; Lees CW
    J Gastroenterol Hepatol; 2021 Aug; 36(8):2067-2075. PubMed ID: 33381875
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association between ustekinumab trough concentrations and biochemical outcomes in patients with Crohn's disease. A real life study.
    Gómez Espín R; Nicolás De Prado I; Gil Candel M; González Carrión M; Rentero Redondo L; Iniesta Navalón C
    Rev Esp Enferm Dig; 2021 Feb; 113(2):110-115. PubMed ID: 33213170
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Normalization of long-term quality of life in Crohn's disease patients receiving ustekinumab.
    Marquès-Camí M; Robles Alonso V; Borruel N; Herrera de Guise C; Mayorga L; Casellas F
    Rev Esp Enferm Dig; 2021 May; 113(5):313-317. PubMed ID: 33213168
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of short- and long-term effectiveness between ustekinumab and vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor therapy.
    Manlay L; Boschetti G; Pereira B; Flourié B; Dapoigny M; Reymond M; Sollelis E; Gay C; Boube M; Buisson A; Nancey S
    Aliment Pharmacol Ther; 2021 Jun; 53(12):1289-1299. PubMed ID: 33909920
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.